EUVIMEDEUVIMED entdecken
Crossref

Design, Docking Study, Synthesis and Preliminary Cytotoxic Study of Novel Isatin-Niflumic acid Derivatives as Possible VEGFR Tyrosine Kinase Inhibitors

Hussein Muneam Sahib, Ammar Abdul Aziz Alibeg

Wiadomości Lekarskie · 30.11.2025 · (11) · 2420-2432

DOI: 10.36740/wlek/212543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiadomości Lekarskie, online erschienen am 30.11.2025. Verfasst von Hussein Muneam Sahib und 1 weiteren Autor:innen. Beteiligte Einrichtung: DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Isatin, Niflumic Acid, Vascular Endothelial Growth Factor Receptor-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Aim: Design, synthesis and cytotoxic evaluation of new series of isatin-niflumic acid derivatives as vascular endothelial growth factor receptor tyrosine kinase inhibitors. Material and methods Materials and Methods: A molecular docking study was performed to assess the binding affinities of the synthesized compounds against the kinase domains of the vascular endothelial growth factor receptor 2. The compounds were synthesized through the esterification process of Niflumic acid, followed by treating the obtained ethyl ester compound with hydrazine monohydrate to form the Niflumic acid hydrazide compound. This compound was further reacted with six Isatin derivatives utilizing the ketone-amine condensation reaction to form the final six new compounds.

Results

Results: The synthesized compounds (I-VI) showed optimum binding affinity (S. score) values ranging from -9.1782 to -9.5120 Kcal/mol and precise binding mode (RMSD) values ranging from 1.0608 to 1.8914 with the active kinase site of the vascular endothelial growth factor receptor 2 (PDB code: 4AG8). At the same time, the cytotoxicity results showed an optimum inhibitory effect (20.87 μM to 78.48 μM) against the A549 (non-small cell lung cancer) and a safer effect (175.49 μM to 280.27 μM) against the MRC-5 (normal lung tissue cells). In contrast to the reference drug (Sunitinib).

Conclusions

Conclusion: The new synthesized compounds (I-VI) are potent vascular endothelial growth factor receptor 2 tyrosine kinase inhibitors, inhibiting cell proliferation, angiogenesis and exhibiting promising anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsIsatinNiflumic AcidVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsHumansMolecular Docking SimulationDrug Design

Stichwörter der Autor:innen

Niflumic acidmolecular dockingVEGFR-2 inhibitorsIsatin derivatives

Substanzen

Protein Kinase InhibitorsIsatinNiflumic AcidVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsKDR protein, human

Autor:innen und Institutionen

  • DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ.
  • DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COLLEGE OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ.

Zitieren

APA

Sahib, H. M., & Alibeg, A. A. A. (2025). Design, Docking Study, Synthesis and Preliminary Cytotoxic Study of Novel Isatin-Niflumic acid Derivatives as Possible VEGFR Tyrosine Kinase Inhibitors. Wiadomości Lekarskie, 2420-2432. https://doi.org/10.36740/wlek/212543

Vancouver

Sahib HM, Alibeg AAA. Design, Docking Study, Synthesis and Preliminary Cytotoxic Study of Novel Isatin-Niflumic acid Derivatives as Possible VEGFR Tyrosine Kinase Inhibitors. Wiadomości Lekarskie. 2025:2420-2432. doi:10.36740/wlek/212543

BibTeX
@article{Sahib2025,
  author = {Sahib, Hussein Muneam and Alibeg, Ammar Abdul Aziz},
  title = {Design, Docking Study, Synthesis and Preliminary Cytotoxic Study of Novel Isatin-Niflumic acid Derivatives as Possible VEGFR Tyrosine Kinase Inhibitors},
  journal = {Wiadomości Lekarskie},
  year = {2025},
  number = {11},
  pages = {2420--2432},
  doi = {10.36740/wlek/212543}
}
Kostenlos starten →